Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer H Law

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Evolution; International Journal of Organic Evolution|October 2, 2002
Recent and ancient asexuality in Timema walkingsticksJennifer H Law, Bernard J Crespi
Molecular Ecology|July 30, 2002
The evolution of geographic parthenogenesis in Timema walking-sticksJennifer H Law, Bernard J Crespi
Breast Cancer Research : BCR|February 8, 2012
Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cellsKaiji Hu, Jennifer H Law, Abbas Fotovati, et al.
JTO Clinical and Research Reports|August 20, 2025
Impact of the COVID-19 Pandemic on Diagnosis and Multidisciplinary Treatment of NSCLC in Ontario, CanadaKirstin Perdrizet, Lisa W Le, Anthea Lau, et al.
Anaerobe|February 12, 2017
Comparison of Clostridium difficile minimum inhibitory concentrations obtained using agar dilution vs broth microdilution methodsChristine J Hastey, Suzanne E Dale, Julia Nary, et al.
Current Oncology (Toronto, Ont.)|August 27, 2021
Reflex ROS1 IHC Screening with FISH Confirmation for Advanced Non-Small Cell Lung Cancer-A Cost-Efficient Strategy in a Public Healthcare SystemMaisam Makarem, Doreen A Ezeife, Adam C Smith, et al.
Translational Oncogenomics|May 7, 2013
Urokinase-type Plasminogen Activator (uPA) is Inhibited with QLT0267 a Small Molecule Targeting Integrin-linked Kinase (ILK)Nancy Dos Santos, Golareh Habibi, Michelle Wang, et al.
Breast Cancer Research : BCR|October 18, 2008
Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypesGolareh Habibi, Samuel Leung, Jennifer H Law, et al.
Asia-Pacific Journal of Clinical Oncology|March 31, 2026
Factors Associated With Long-Term Survivors With Epidermal Growth Factor Receptor Positive Non-Small Cell Lung Cancer Treated With First or Second-Generation Tyrosine Kinase Inhibitors: A Canadian Multi-Center CohortHeather Halperin, Amanda J W Gibson, Ali Hussein, et al.
Plos One|September 17, 2010
Molecular decoy to the Y-box binding protein-1 suppresses the growth of breast and prostate cancer cells whilst sparing normal cell viabilityJennifer H Law, Yvonne Li, Karen To, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Evolution; International Journal of Organic Evolution|October 2, 2002
Recent and ancient asexuality in Timema walkingsticksJennifer H Law, Bernard J Crespi
Molecular Ecology|July 30, 2002
The evolution of geographic parthenogenesis in Timema walking-sticksJennifer H Law, Bernard J Crespi
Breast Cancer Research : BCR|February 8, 2012
Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cellsKaiji Hu, Jennifer H Law, Abbas Fotovati, et al.
JTO Clinical and Research Reports|August 20, 2025
Impact of the COVID-19 Pandemic on Diagnosis and Multidisciplinary Treatment of NSCLC in Ontario, CanadaKirstin Perdrizet, Lisa W Le, Anthea Lau, et al.
Anaerobe|February 12, 2017
Comparison of Clostridium difficile minimum inhibitory concentrations obtained using agar dilution vs broth microdilution methodsChristine J Hastey, Suzanne E Dale, Julia Nary, et al.
Current Oncology (Toronto, Ont.)|August 27, 2021
Reflex ROS1 IHC Screening with FISH Confirmation for Advanced Non-Small Cell Lung Cancer-A Cost-Efficient Strategy in a Public Healthcare SystemMaisam Makarem, Doreen A Ezeife, Adam C Smith, et al.
Translational Oncogenomics|May 7, 2013
Urokinase-type Plasminogen Activator (uPA) is Inhibited with QLT0267 a Small Molecule Targeting Integrin-linked Kinase (ILK)Nancy Dos Santos, Golareh Habibi, Michelle Wang, et al.
Breast Cancer Research : BCR|October 18, 2008
Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypesGolareh Habibi, Samuel Leung, Jennifer H Law, et al.
Asia-Pacific Journal of Clinical Oncology|March 31, 2026
Factors Associated With Long-Term Survivors With Epidermal Growth Factor Receptor Positive Non-Small Cell Lung Cancer Treated With First or Second-Generation Tyrosine Kinase Inhibitors: A Canadian Multi-Center CohortHeather Halperin, Amanda J W Gibson, Ali Hussein, et al.
Plos One|September 17, 2010
Molecular decoy to the Y-box binding protein-1 suppresses the growth of breast and prostate cancer cells whilst sparing normal cell viabilityJennifer H Law, Yvonne Li, Karen To, et al.
Pageof 3